The antiviral therapeutic area continues to rapidly generate meaningful new chemical entities; for example, for HIV alone more than 25 drugs have been approved, and in the next few years many individual drugs and single tablet regimens will be approved for the treatment of hepatitis C virus infection. The increasing success in the antiviral area could be due to targeting drugs at "non-self" genomes and to the patient population that is tolerant of manageable side effects and adaptable to inconvenient dosing.

Aimed at medicinal chemists and emerging drug discovery scientists, the book is organized according to the various strategies deployed for the discovery and optimization of initial lead compounds. The book focuses on capturing tactical aspects of problem solving in antiviral drug design, an approach that holds special appeal for those engaged in antiviral drug development, but also appeals to the broader medicinal chemistry community based on its focus on tactical aspects of drug design.

Section I: Phenotypic Screening to Discover Antiviral Agents; HCV NS5A Inhibitors; RSV fusion Inhibitors; Dengue Virus Inhibitors; Pox Virus Inhibitors; TLR-7 Agonists as Inducers of interferon-a; Section II: Biochemical Screening to Discover Antiviral Agents; HIV Integrase Inhibitors; Inhibitors of Virus Capsid Formation; Ion channels as Antiviral Targets; Section III: Structure- and Physical Property-Based Design of Antiviral Agents; Non-nucleoside HCV NS5B inhibitors; HCV NS3 Protease Inhibitors; HIV Integrase LEDGF inhibitors; Section IV: Delivery of Antiviral Agents; Prodrugs of Nucleoside Analogs for HIV and HCV; Cobicistat and Ritonavir as PK Enhancers for Antiviral drugs; Single Tablet Regimens of Antiviral Agents for HIV and HCV;